10 papers and 1 clinical trial exploring esketamine as a treatment for adolescents.
Esketamine (Spravato) is the S-enantiomer of ketamine, approved as an intranasal treatment for treatment-resistant depression and MDD with acute suicidal ideation. It is administered under clinical supervision with post-dose monitoring and has reached over $1.6 billion in annual sales.
Full Esketamine profileAdolescents are a developing-brain, vulnerable population that the modern psychedelic field has mostly studied from the outside: almost all psychedelic trials enrol adults, not minors. The one mature clinical thread in under-18s is ketamine and esketamine for depression and acute suicidality, where benefits are real but modest and often matched by active-placebo arms. For classic psychedelics like psilocybin, LSD and MDMA there is essentially no controlled evidence in adolescents, and the developing brain raises safety questions that adult data cannot answer.
Full Adolescents profile